Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody

While glyco-engineered monoclonal antibodies (mAbs) with improved antibody-dependent cell-mediated cytotoxicity (ADCC) are reaching the market, extensive efforts have also been made to improve their pharmacokinetic properties to generate biologically superior molecules. Most therapeutic mAbs are hum...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Monnet, Céline, Jorieux, Sylvie, Souyris, Nathalie, Zaki, Ouafa, Jacquet, Alexandra, Fournier, Nathalie, Crozet, Fabien, de Romeuf, Christophe, Bouayadi, Khalil, Urbain, Rémi, Behrens, Christian K, Mondon, Philippe, Fontayne, Alexandre
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2014
Témata:
Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984331/
https://ncbi.nlm.nih.gov/pubmed/24492301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.27854
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky